ATCC (company)

Agathos Biologics Launches Recombinant Adeno-Associated Virus Production Service Using Novel AE1-BHK Cell Line

Retrieved on: 
Wednesday, March 6, 2024
Health, Genetics, Other Science, Research, Science, Pharmaceutical, Biotechnology, Plasmid, ATCC, Multimedia, Sale, Transfection, Cell, Antibody, HEK293, Patent, Poster, Immortalised cell line, ATCC (company), AAV, Vaccine

Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK.

Key Points: 
  • Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK.
  • View the full release here: https://www.businesswire.com/news/home/20240305885603/en/
    The AE1-BHK cell line was developed by stable transfection of the BHK-21 (C-13) cell line (ATCC®, catalog number ATCC CCL-10™) with the adenoviral E1 gene.
  • “The launch of our custom rAAV service and the first sale of rAAV made using our AE1-BHK cell line is a significant milestone for the company,” said James Brown, CEO and co-founder of Agathos Biologics.
  • “To our knowledge, this is the first sale of rAAV produced using triple transfection in a cell line other than HEK293.

Cell Line Development Market Research Report 2023-2030 Featuring Key Players - Thermo Fisher Scientific, Corning, Lonza, Creative BioLabs., WuXi PharmaTech, Sartorius, Merck, Berkeley Lights, Danaher - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 7, 2023
Health, Pharmaceutical, CLD, Research, Immortalised cell line, GMP, Thermo Fisher Scientific, Fujifilm, Type, Coronavirus, Application, Fujifilm Diosynth Biotechnologies, ATCC (company), Novartis, Sigma-Aldrich, Human, Growth, ATCC, Fine chemical, Pharmaceutical industry, Mobile phone, Vaccine, Nusinersen

Rising use of new healthcare technology and rising cancer incidences, create more attractive and lucrative growth prospects for the CLD market.

Key Points: 
  • Rising use of new healthcare technology and rising cancer incidences, create more attractive and lucrative growth prospects for the CLD market.
  • The expansion and growth of the biologics sector will also be a major CLD market development determinant.
  • For example, CYTENA, a BICO subsidiary, introduced a new platform for entirely automated stable cell line development in October 2021.
  • However, the high capital expenses and expenditure needed to construct research and development capabilities would be a barrier to the cell line development industry.

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Wednesday, November 1, 2023
Research, AD, Food, Health care, Biomarker, ATCC, Macrophage, World Intellectual Property Organization, Data, White matter, Phase, MHRA, MRI, MDS, CELL, Hereditary leiomyomatosis and renal cell cancer syndrome, Prostate cancer, Dementia, China International Search and Rescue Team, ATCC (company), Phagocytosis, EEG, Cancer, Patient, MS, BOCA, Human, Neurodegenerative disease, Conference, CTA, Patent Cooperation Treaty, AAIC, PCT, NK, Brain, Remyelination, Grey, AML, Carcinoma, FDA, IND, Medication, CNS, Treatment-resistant depression, Drug development, Pharmacotherapy, Neuroinflammation, WIPO, Cross, Cognition, Vaccine, Pharmaceutical industry, Medical imaging, Cryptocurrency, Health, Immunotherapy, Disease

BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.
  • Recruitment of the trial is increasing and the company anticipates results of the Phase II program towards the end of 2024.
  • Other expense was approximately $0.0 million for the quarter ended September 30, 2023, compared to approximately $0.3 million during the quarter ended September 30, 2022.
  • Please ask for the INmune Bio Third Quarter Conference Call when reaching an operator.

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority

Retrieved on: 
Tuesday, October 31, 2023
Patient, IND, PSA, Patent, Leukemia, Progression-free survival, Biomarker, Art, Ligand, World Intellectual Property Organization, CD15, Invention, CELL, Hematological Cancer Research Investment and Education Act, Patent Cooperation Treaty, Cell, EPO, Administration, China International Search and Rescue Team, Disease, ATCC (company), NK, Cancer, WIPO, CT, Blood, TME, General counsel, CD2, Immunosuppression, Hypoxia, Insurance, Vaccine, Pharmaceutical industry

Boca Raton, Florida, Oct. 31, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced an update regarding the company’s patent covering its proprietary cell line, “INB16”, as well as the therapeutic composition comprising replication-incompetent INB16 cells known as “INKmune™” and methods of treating cancer by administering INKmune™, with a goal of achieving in vivo priming of natural killer (NK) cells to enhance the ability of a patient’s own NK-cells to effect cancer surveillance, recognition, and killing.

Key Points: 
  • INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent application covering, among other things, its proprietary cell line, INB16, and the INKmune™ therapeutic composition.
  • The application discloses and claims the novel INB16 cell line on deposit with the American Type Culture Collection, as well as compositions comprising replication incompetent INB16 cells (“INKmune™”) and methods of treating cancer in patients by administering INKmune™.
  • “Patents covering novel cell lines are somewhat rare in practice and form a very small number of total patents issued,” said Joshua Schoonover, Esq., in-house General Counsel for the Company.
  • INB16 is a tumor cell line which is relatively insensitive to killing by natural killer (NK) cells from healthy donors and from patients.

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

Retrieved on: 
Wednesday, July 12, 2023
Intercept, Bachelor, Drug development, Therapy, Senior, Pharmacia, Virology, Biotechnology, ATCC, Viral, Pharmacia & Upjohn, ATCC (company), Doctor of Philosophy, Chemistry, Development, HBV, Management, Arbutus

“We are excited to welcome Dr. Rewolinski to the Arbutus Board,” said William Collier, President and Chief Executive Officer of Arbutus.

Key Points: 
  • “We are excited to welcome Dr. Rewolinski to the Arbutus Board,” said William Collier, President and Chief Executive Officer of Arbutus.
  • She currently serves as a board member for Lannett Company, Inc., and American Type Culture Collection (ATCC).
  • Dr. Rewolinski, commented, “This is an exciting time to join the Board of Arbutus.
  • I look forward to working with my fellow Board members to support Arbutus in its continued efforts to develop treatments for HBV and coronaviruses.”